| 翻訳と辞書 |
Prasugrel
Prasugrel (trade name Effient in the US and India, and Efient in the EU) is a platelet inhibitor developed by Daiichi Sankyo Co. and produced by Ube and currently marketed in the United States in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). Prasugrel was approved for use in Europe in February 2009, and is currently available in the UK. On July 10, 2009, the US Food and Drug Administration approved the use of prasugrel for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI.〔Baker WL, White CM. Role of Prasugrel, a Novel P2Y12 Receptor Antagonist, in the Management of Acute Coronary Syndromes. ''American Journal of Cardiovascular Drugs'' Aug 1, 2009; 9 (4): 213-229. (Link text )〕
==Medical uses==
Prasugrel does not change the risk of death when given to people who have had a STEMI or NSTEMI. Prasagrel does however increase the risk of bleeding and may decrease the risk of further cardiovascular problems. Thus routine use is of questionable value.
AHA/ACC NSTE-ACS Guidelines state: "Prasagrel should not be administered to patients with prior history of stroke or transient ischemic attack (III Harm)
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Prasugrel」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|